Adverse reactions related to drugs for headache treatment: Clinical impact

European Journal of Clinical Pharmacology

Volumn 60, Issue 12, 2005, Pages 893-900

  Ferrari, Anna ^a   Ottani, Alessandra ^a   Bertolini, Alfio ^a   Cicero, Arrigo Francesco Giuseppe ^a   Coccia, Ciro Pio Rosario ^a   Leone, Sheila ^a   Sternieri, Emilio ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adverse drug reaction; Headache; Prophylactic treatment

Indexed keywords

AMITRIPTYLINE; ANALGESIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUTALBITAL; CAFFEINE; CENTRAL NERVOUS SYSTEM AGENTS; CITALOPRAM; CODEINE; ERGOT DERIVATIVE; FLUNARIZINE; FLUOXETINE; FLUVOXAMINE; INDOMETACIN; LITHIUM; METOCLOPRAMIDE; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PAROXETINE; PROCHLORPERAZINE; PROPRANOLOL; RIZATRIPTAN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL; ZOLMITRIPTAN;

ABDOMINAL PAIN; ACCOMMODATION PARALYSIS; ADOLESCENT; ADULT; AGED; ALOPECIA; ANORGASMIA; ANXIETY; ARTICLE; ASTHENIA; CARDIOVASCULAR SYMPTOM; CHRONIC TENSION HEADACHE; CLINICAL PRACTICE; CLUSTER HEADACHE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DRUG CLASSIFICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHORIA; EPISODIC TENSION HEADACHE; ERUCTATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARING IMPAIRMENT; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPOTENSION; INCREASED APPETITE; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; METABOLIC DISORDER; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MUSCLE SPASM; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; OUTPATIENT; PARESTHESIA; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PRURITUS; SCHOOL CHILD; SIDE EFFECT; SKIN EDEMA; SKIN MANIFESTATION; SOMNOLENCE; SUPPOSITORY; TACHYCARDIA; THORAX DISEASE; TRANSFORMED MIGRAINE; URINARY FREQUENCY; UROGENITAL TRACT DISEASE; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALGESICS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; CHILD; FEMALE; HEADACHE DISORDERS; HUMANS; MALE; MIDDLE AGED;

EID: 15244340224     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-004-0864-7     Document Type: Article

References (89)

1. Rasmussen BK (1995) Epidemiology of headache. Cephalalgia 15:45-68
2. MacGregor EA, Brandes J, Eikermann A (2003) Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache 43:19-26
3. Boardman HF, Thomas E, Croft PR, Millson DS (2003) Epidemiology of headache in an English district. Cephalalgia 23:129-137
4. Edmeads J, Findlay H, Tugwell P, Pryse-Phillips W, Nelson RF, Murray TJ (1993) Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci 20:131-137
5. Kryst S, Sherl E (1994) A population-based survey of the social and personal impact of headache. Headache 34:344-350
6. Dahlöf CG, Solomon GD (1998) The burden of migraine to the individual sufferer. A review. Eur J Neurol 5:525-533
7. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML (1999) Burden of migraine in the United States: disability and economic costs. Arch Intern Med 159:813-818
8. Lavados PM, Tenhamm E (2001) Consulting behaviour in migraine and tension-type headaches sufferers: a population survey in Santiago, Chile. Cephalalgia 21:733-737
9. Mannix LK (2001) Epidemiology and impact of primary headache disorders. Med Clin North Am 85:887-895
10. Rasmussen BK (2001) Epidemiology of headache. Cephalalgia 21:774-777
11. Pop PH, Gierveld C, Karis HA, Tiedink HG (2002) Epidemiological aspects of headache in a workplace setting and the impact on the economic loss. Eur J Neurol 9:171-174
12. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton R B (2003) The prevalence and disability burden of adult migraine in England and their relationship to age, gender and ethnicity. Cephalalgia 23:519-527
13. Leonardi M, Musicco M, Nappi G (1998) Headache as a major public health problem: current status. Cephalalgia 18(Suppl 21):66-69
14. Sheftell FD, Tepper SJ (2002) New paradigms in the recognition and acute treatment of migraine. Headache 42:58-69
15. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ (2000) The impact of migraine on quality of life in the general population: the GEM study. Neurology 55:624-629
16. Duru G, Auray JP, Gaudin AF, Dartigues JF, Henry P, Lanteri-Minet M, Lucas C, Pradalier A, Chazot G, Hasnaoui AE (2004) Impact of headache on quality of life in a general population survey in France (GRIM2000 study). Headache 44:571-580
17. Silberstein SD, for the US Headache Consortium (2000) Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55:754-762
18. Evans, RW, Lipton RB (2001) Topics in migraine management: a survey of headache specialists highlights some controversies. Neurol Clin 19:1-21
19. Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine-current understanding and treatment. N Engl J Med 346:257-270
20. Krymchantowski AV (2004) Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurol 4:4
21. Pringsheim T, Edmeads J (2004) Effective treatment of migraine. Terminating acute attacks, reducing their frequency. Postgrad Med 115:28-30
22. Bigal ME, Lipton RB, Stewart WF (2004) The epidemiology and impact of migraine. Curr Neurol Neurosci Rep 4:98-104
23. Pascual J (1999) New prospects in the treatment of migraine. Neurologia 14(Suppl 6):26-35
24. Diener HC, Limmroth V (2001) Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 10:1831-1845
25. Geraud G, Keywood C, Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 43:376-388
26. Ramadan NM, Schultz LL, Gilkey SJ (1997) Migraine prophylactic drugs: proof of efficacy, utilization and cost. Cephalalgia 17:73-80
27. Adelman JU, Adelman RD (2001) Current options for the prevention and treatment of migraine. Clin Ther 23:772-788
28. Bigal ME, Krymchantowski AV, Rapoport AM (2003) New developments in migraine prophylaxis. Expert Opin Pharmacother 4:433-443
29. Granella F. Cavallini A, Sandrini G, Manzoni GC, Nappi G (1998) Long-term outcome of migraine. Cephalalgia 18(Suppl 21):30-33
30. Becker WJ (1999) Evidence based migraine prophylactic drug therapy. Can J Neurol Sci 26(Suppl 3):S27-S32
31. Tfelt-Hansen P (1997) How to define the best efficacy parameters for migraine. Cephalalgia 17(Suppl 17):6-9
32. Goadsby PJ (1999) The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci 26(Suppl 3):20-26
33. Wood AJJ, Stein CM, Woosley R (1998) Making medicines safer - the need for an independent drug safety board. N Engl J Med 339:1851-1854
34. Ioannidis JP, Lau J (2001) Completeness of safety reporting in randomized trials. An evaluation of seven medical areas. JAMA 285:437-443
35. Ioannidis JP, Lau J (2002) Improving safety reporting from randomised trials. Drug Saf 25:77-84
36. Rokicki LA, Holroyd KA (1994) Factors influencing treatment-seeking behaviour in problem headache sufferers. Headache 34:429-434
37. Friedman MA, Woodcock J, Lumpkin MM, Shuren EJ, Hass AE, Thompson LJ (1999) The safety of newly approved medicines. Do recent market removals mean there is a problem? JAMA 28:1728-1734
38. Matchar DB, Mc Crory DC, Gray RN (2000) Toward evidence-based management of migraine. JAMA 284:2640-2641
39. Silberstein SD (1997) Preventive treatment of migraine: an overview. Cephalalgia 17:67-72
40. Solomon GD (2001) Management of primary headache: serendipity and science. Cleve Clin J Med 68:904-912
41. O'Donnell F, Gerard G, Kunkel R, Hu XH (1999) Migraine care delivered by primary care physicians and headache specialists. Headache S1:A373
42. Brandes JL (2002) Global trends in migraine care: results from MAZE survey. CNS Drugs 16(Suppl 1):13-18
43. Blumenfeld A, Tischio M (2003) Center of excellence for headache care: group model at Kaiser Permanente. Headache 43:431-440
44. Headache Classification Committee of the International Headache Society (1998) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(Suppl 7):9-96
45. Mathew NT (1993) Transformed migraine. Cephalalgia 13(Suppl 12):78-83
46. World Health Organization (1969) International drug monitoring: the role of the hospital. Tech Rep Ser 425:5-25
47. World Health Organization (1981) Cancer treatment: WHO recommendations for grading of acute and subacute toxicity. Cancer 47:207-214
48. Karch FE, Lasagna L (1975) Adverse drug reactions: a critical review. JAMA 234:1236-1241
49. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239-245
50. Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, Peterson LA, Small SD, Sweitzer BJ, Vander Vliet M, Leape LL (1999) Patient risk factors for adverse drug events in hospitalized patients. ADE prevention study group. Arch Intern Med 159:2553-2560
51. van den Bemt PM, Egberts AC, Lenderink AW, Verzijl JM, Simons KA, van der Pol WS, Leufkens HG (2000) Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci 22:62-66
52. Gurwitz JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C, Fish LS, Garber L, Kelleher M, Bates DW (2003) Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 289:1107-1116
53. Gandhi TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu K, Federico F, Leape LL, Bates DW (2003) Adverse drug events in ambulatory care. N Engl J Med 348:1556-1564
54. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205
55. Atuah KN, Hughes D, Pirmohamed M (2004) Clinical pharmacology: special safety considerations. Drug Saf 27:535-554
56. Ferrari A, Pasciullo G, Savino G, Cicero AFG, Ottani A, Bertolini A, Sternieri E (2004) Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study. Cephalalgia 24:356-362
57. Martindale: The complete drug reference 32nd edition (1999) Parfitt K (ed) Pharmaceutical Press, MA, pp 45-48
58. Magni G (1991) The use of antidepressants in the treatment of chronic pain. A review of the current evidence. Drugs 42:730-748
59. Adly C, Straumanis J, Chesson A (1992) Fluoxetine prophylaxis of migraine. Headache 32(Suppl 2):7-12
60. Bank J (1994) A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 34:476-478
61. Zagami SA (1995) Chronic tension type headache. CNS Drugs 4:90-98
62. Jick H, Miettinen OS, Shapiro S, Lewis GP, Siskind V, Slone D (1970) Comprehensive drug surveillance. JAMA 213:1455-1460
63. Neidig JL, Koletar SL (2001) Safety reporting in clinical trials. JAMA 285:2077-2078
64. Gallagher RM, Kunkel R (2003) Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 43:36-43
65. Celentano DD, Stewart WF, Lipton RB, Reed ML (1992) Medication use and disability among migraneurs: a national probability sample survey. Headache 32:223-232
66. Von Korff M, Black LK, Saunders K, Galer BS (1999) Headache medication-use among primary care headache patients in a health maintenance organization. Cephalalgia 19:575-580
67. Lipton RB, Stewart WF, Scher AI (2001) Epidemiology and economic impact of migraine. Curr Med Res Opin 17(Suppl 1):4-12
68. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ (2001) Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358:1668-1675
69. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loufti H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J (2004) The triptan cardiovascular safety expert panel. Headache 44:414-425
70. Wenzel R, Dorteh M, Cady R, Lefland JH, Diamond S (2004) Migraine headache misconceptions: barriers to effective care. Pharmacotherapy 24:638-648
71. Hall GC, Brown MM, Mo J, MacRae KD (2004) Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 62:563-568
72. Wang JT, Barr CE, Goldfarb SD (2002) Impact of chest pain on cost of migraine treatment with almotriptan and sumatriptan. Headache 42(Suppl 1):38-43
73. Williams D, Cahill T, Dowson A, Fearon H, Lipscombe S, O'Sullivan E, Rees T, Strang C, Valori A, Watson D (2002) Usage of triptans among migraine patients: an audit in nine GP practices. Curr Med Res Opin 18:1-9
74. Lucas C, Auray JP, Gaudin AF, Dartigues JF, Duru G, Henry P, Lantéri-Minet M, Pradalier A, Chazot G, El Hasnaoui A (2004) Use and misuse of triptans in France: data from the GRIM2000 population survey. Cephalalgia 24:197-205
75. Task Force of the International Headache Society (1977) Organization and delivery of services to headache patients. Cephalalgia 17:702-710
76. Fisher S, Bryant SG (1990) Postmarketing surveillance: accuracy of patient drug attribution judgments. Clin Pharmacol Ther 48:102-107
77. Fisher S, Bryant SG, Kent TA, Davis JE (1994) Patient drug attributions and postmarketing surveillance. Pharmacotherapy 14:202-209
78. Barsky AJ, Saintfort R, Rogers MP, Borus JF (2002) Non-specific medication side effects and the ncebo phenomenon. JAMA 287:622-627
79. Tierney WM (2003) Adverse outpatient drug events - a problem and an opportunity. N Engl J Med 348:1587-1589
80. Trontell A (2004) Expecting the unexpected-drug safety, pharmacovigilance, and prepared mind. N Engl J Med 351:1385-1387
81. Celentano DD, Linet MS, Stewart WF (1990) Gender differences in the experience of headache. Soc Sci Med 30:1289-1295
82. Stewart WF, Lipton RB, Celentano DD, Reed ML (1992) Prevalence of migraine headache in the United States: relation to age, income, race, and other sociodemographic factors. JAMA 267:64-69
83. Stewart WF, Celentano DD, Linet MS (1989) Disability, physician consultation, and use of prescription medication in a population-based study of headache. Biomed Pharmacother 43:711-718
84. Linet MS, Celentano DD, Stewart WF (1991) Headache characteristics associated with physician consultation: a population based survey. Am J Prev Med 7:40-46
85. Wang SJ, Fuh JL, Young YH, Lu SR, Shia BC (2001) Frequency and predictors of physician consultations for headache. Cephalalgia 21:25-30
86. Ross SD (2001) Drug-related adverse events. A readers' guide to assessing literature reviews and meta-analyses. Arch Intern Med 161:1041-1046
87. Dodick DW (2003) Patient focused migraine management: establishing needs. Drugs Today 39(Suppl D):3-9
88. Potrebic S (2004) The changing face of migraine. Curr Pain Headache Rep 8:85-90
89. Ziegler DK, Mosier MC, Buenaver M, Okuyemi K (2001) How much information about adverse effects of medication patients want from physicians? Arch Intern Med 161:706-713